AG
LXRX icon

Aperio Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Aperio Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$50K Buy
+14,548
New +$27.8K ﹤0.01% 2412
2019
Q3 		– Sell
-3,824
Closed -$24K – 2562
2019
Q2 		$24K Buy
+3,824
New +$22.9K ﹤0.01% 2666
2018
Q4 		– Sell
-15,540
Closed -$166K – 2317
2018
Q3 		$166K Sell
15,540
-512
-3% -$5.87K ﹤0.01% 2213
2018
Q2 		$193K Sell
16,052
-3,218
-17% -$32.9K ﹤0.01% 2170
2018
Q1 		$165K Buy
19,270
+6,377
+49% +$59K ﹤0.01% 2172
2017
Q4 		$127K Buy
+12,893
New +$134K ﹤0.01% 2195

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aperio Group's LXRX Position: Q4 2020 in Review

Aperio Group opened a new position in Lexicon Pharmaceuticals (LXRX) in Q4 2020: 14,548 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #2412 among its holdings. This is a return to the name: Aperio Group previously reported a position in LXRX as recently as Q2 2019.

Aperio Group first reported a position in LXRX in Q4 2017 and has held it in 6 quarters since. The position peaked at $193K in Q2 2018. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2020.

  • Aperio Group held 14,548 shares of Lexicon Pharmaceuticals worth $50K as of Q4 2020.
  • Lexicon Pharmaceuticals was a new Aperio Group position in Q4 2020.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2412 holding.
  • Aperio Group first reported a position in Lexicon Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
  • Aperio Group's Lexicon Pharmaceuticals position peaked at $193K in Q2 2018.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.